These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 26881769)

  • 41. Update on 1-benzylpiperazine (BZP) party pills.
    Monteiro MS; Bastos Mde L; Guedes de Pinho P; Carvalho M
    Arch Toxicol; 2013 Jun; 87(6):929-47. PubMed ID: 23685794
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A New Differential Diagnosis: Synthetic Cannabinoids-Associated Acute Renal Failure.
    Gudsoorkar VS; Perez JA
    Methodist Debakey Cardiovasc J; 2015; 11(3):189-91. PubMed ID: 26634029
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Review of detection frequency and type of synthetic cannabinoids in herbal compounds analyzed by Istanbul Narcotic Department of the Council of Forensic Medicine, Turkey.
    Gurdal F; Asirdizer M; Aker RG; Korkut S; Gocer Y; Kucukibrahimoglu EE; Ince CH
    J Forensic Leg Med; 2013 Aug; 20(6):667-72. PubMed ID: 23910858
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Psychosis and synthetic cannabinoids.
    Deng H; Verrico CD; Kosten TR; Nielsen DA
    Psychiatry Res; 2018 Oct; 268():400-412. PubMed ID: 30125871
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New designer drugs (synthetic cannabinoids and synthetic cathinones): review of literature.
    Cottencin O; Rolland B; Karila L
    Curr Pharm Des; 2014; 20(25):4106-11. PubMed ID: 24001292
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Synthetic Drugs - An Overview of Important and Newly Emerging Substances].
    Betzler F; Heinz A; Köhler S
    Fortschr Neurol Psychiatr; 2016 Nov; 84(11):690-698. PubMed ID: 27846654
    [No Abstract]   [Full Text] [Related]  

  • 47. Designer drugs: a medicinal chemistry perspective.
    Carroll FI; Lewin AH; Mascarella SW; Seltzman HH; Reddy PA
    Ann N Y Acad Sci; 2012 Feb; 1248():18-38. PubMed ID: 22092008
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Effect and occurrence of synthetic cannabinoids].
    Tuv SS; Strand MC; Karinen R; Øiestad EL; Christophersen AS; Vindenes V
    Tidsskr Nor Laegeforen; 2012 Oct; 132(20):2285-8. PubMed ID: 23736196
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment.
    Tait RJ; Caldicott D; Mountain D; Hill SL; Lenton S
    Clin Toxicol (Phila); 2016; 54(1):1-13. PubMed ID: 26567470
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analytical toxicology of emerging drugs of abuse--an update.
    Meyer MR; Peters FT
    Ther Drug Monit; 2012 Dec; 34(6):615-21. PubMed ID: 23131695
    [TBL] [Abstract][Full Text] [Related]  

  • 51. How MDMA's pharmacology and pharmacokinetics drive desired effects and harms.
    Michael White C
    J Clin Pharmacol; 2014 Mar; 54(3):245-52. PubMed ID: 24431106
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 'Legal highs'--novel and emerging psychoactive drugs: a chemical overview for the toxicologist.
    Gibbons S
    Clin Toxicol (Phila); 2012 Jan; 50(1):15-24. PubMed ID: 22248120
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The behavioral profile of spice and synthetic cannabinoids in humans.
    Müller HH; Kornhuber J; Sperling W
    Brain Res Bull; 2016 Sep; 126(Pt 1):3-7. PubMed ID: 26548494
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Spicing things up: synthetic cannabinoids.
    Spaderna M; Addy PH; D'Souza DC
    Psychopharmacology (Berl); 2013 Aug; 228(4):525-40. PubMed ID: 23836028
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Simultaneous polysubstance use among Danish 3,4-methylenedioxymethamphetamine and hallucinogen users: combination patterns and proposed biological bases.
    Licht CL; Christoffersen M; Okholm M; Damgaard L; Fink-Jensen A; Knudsen GM; Erritzoe D
    Hum Psychopharmacol; 2012 Jul; 27(4):352-63. PubMed ID: 22696164
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epidemiology of adolescent Salvia divinorum use in Canada.
    Currie CL
    Drug Alcohol Depend; 2013 Feb; 128(1-2):166-70. PubMed ID: 22967837
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Case series: Salvia divinorum as a potential addictive hallucinogen.
    El-Khoury J; Baroud E
    Am J Addict; 2018 Apr; 27(3):163-165. PubMed ID: 29596726
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Psychosis and severe rhabdomyolysis associated with synthetic cannabinoid use: A case report.
    Durand D; Delgado LL; de la Parra-Pellot DM; Nichols-Vinueza D
    Clin Schizophr Relat Psychoses; 2015 Jan; 8(4):205-8. PubMed ID: 23518784
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Association of Salvia divinorum and Psychotic Disorders: A Review of the Literature and Case Series.
    El-Khoury J; Sahakian N
    J Psychoactive Drugs; 2015; 47(4):286-92. PubMed ID: 26317561
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Investigating the 'bath salt' panic: the rarity of synthetic cathinone use among students in the United States.
    Stogner JM; Miller BL
    Drug Alcohol Rev; 2013 Sep; 32(5):545-9. PubMed ID: 23718639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.